STONY BROOK, NY, March 28, 2019 – Triple-negative breast cancer is the most aggressive subtype of the disease, and people who have this form of breast cancer often end up with tumor recurrence and metastatic disease despite taking standard forms of chemotherapy. Now a team of researchers led by Lori Chan, PhD, Assistant Professor in the Department of Pharmacological Sciences in the Renaissance School of Medicine at Stony Brook University, have identified a specific gene involved in the cancer stem cell (CSC) population process of triple-negative breast cancer. By blocking this gene’s action, tumor response to chemotherapy is improved. Their findings, published in Cell Death & Disease, illustrate a potential new way to treat incurable triple-negative breast cancer.
The problem with triple-negative breast cancer is that the tissue making up this form of the disease harbors enriched CSC populations in tumors. Current chemotherapies to treat triple-negative breast cancer kill the cancer but spare much of the CSC populations, which trigger recurrence.
“We identified a core molecular pathway that controls CSC activity and a key gene in that process called USP2,” said Dr. Chan. “USP2 is an essential gene that upregulates CSCs in triple-negative breast cancer. We used a genetic approach to block the action of USP2, and by doing that discovered this eliminates the CSC population and re-sensitizes the tumor response to chemotherapy.”
Therefore, by blocking this gene chemotherapy resistance is reduced, or eliminated, which potentially is a curative way to treat the disease, Dr. Chan emphasized. Unlike with other forms of breast cancer, hormonal or antibody therapies against triple-negative breast cancer are not effective when there is tumor recurrence.
Dr. Chan’s co-investigators include Jiabei He, a doctoral student in the Department of Pharmacological Sciences, other scientists from Pharmacological Sciences and the Stony Brook University Cancer Center, and researchers in the Department of Pathology and Cell Biology at Columbia University Medical Center.
The research is supported in part by grants from the National Institutes of Health (ROI CA211912), the New York State Department of Health (C31845GG), and the Susan G. Komen Breast Cancer Foundation and Carol M. Baldwin Breast Cancer Research Fund.
Stony Brook University, widely regarded as a SUNY flagship, is going beyond the expectations of what today’s public universities can accomplish. Since its founding in 1957, this young university has grown to become one of only four University Center campuses in the State University of New York (SUNY) system with more than 25,700 students and 2,500 faculty members, and 18 NCAA Division I athletic programs. Our faculty have earned numerous prestigious awards, including the Nobel Prize, Pulitzer Prize, Indianapolis Prize for animal conservation, Abel Prize and the inaugural Breakthrough Prize in Mathematics. The University offers students an elite education with an outstanding return on investment: U.S.News & World Report ranks Stony Brook among the top 50 public universities in the nation. Its membership in the Association of American Universities (AAU) places Stony Brook among the top 62 research institutions in North America. As part of the management team of Brookhaven National Laboratory, the University joins a prestigious group of universities that have a role in running federal R&D labs. Stony Brook University is a driving force in the region’s economy, generating nearly 60,000 jobs and an annual economic impact of $6.4 billion. Our state, country and world demand ambitious ideas, imaginative solutions and exceptional leadership to forge a better future for all. The students, alumni, researchers and faculty of Stony Brook University are prepared to meet this challenge.